Growth hormone secretagogues (GHSs) are a class of compounds that stimulate the release of growth hormone (GH) from the anterior pituitary gland. Three of the most widely studied GHSs in peptide research are CJC-1295 (a growth hormone releasing hormone analog), Ipamorelin (a selective ghrelin receptor agonist), and GHRP-6 (growth hormone releasing peptide-6). This article provides a comparative overview of these three peptides based on published research literature.
Background: The Growth Hormone Axis
Growth hormone release is regulated by two primary hypothalamic peptides:
- GHRH (Growth Hormone Releasing Hormone): Stimulates GH release by binding to GHRH receptors on somatotroph cells in the anterior pituitary
- Somatostatin (SST): Inhibits GH release by binding to somatostatin receptors
A third regulatory pathway was discovered in the 1990s:
- Ghrelin / GHS-R pathway: Ghrelin (and synthetic ghrelin mimetics) stimulates GH release by binding to the Growth Hormone Secretagogue Receptor (GHS-R1a)
CJC-1295 acts through the GHRH pathway, while Ipamorelin and GHRP-6 act through the ghrelin/GHS-R pathway. Understanding this distinction is essential for interpreting research results.
CJC-1295
Overview
CJC-1295 is a synthetic analog of GHRH (growth hormone releasing hormone, also known as GRF 1-29) with modifications that dramatically extend its half-life.
Two forms exist:
- CJC-1295 with DAC (Drug Affinity Complex): Contains a maleimidopropionic acid-lysine linker that binds covalently to serum albumin after injection, extending the half-life to approximately 6-8 days in animal models
- CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF): Has amino acid substitutions at positions 2, 8, 15, and 27 that resist enzymatic degradation, with a half-life of approximately 30 minutes
Molecular weight: 3367.97 Da (without DAC)
Mechanism of Action
CJC-1295 binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release through a cAMP-dependent signaling pathway. Because it acts through the physiological GHRH receptor, CJC-1295 stimulates GH release in a pulsatile pattern that resembles natural GH secretion — this is considered advantageous compared to exogenous GH administration, which produces non-physiological, constant-level GH exposure.
Key Research Findings
Animal studies:
- In rodent models, CJC-1295 (with DAC) produced sustained elevation of GH and IGF-1 levels for several days after a single administration
- The sustained GH elevation correlated with increased lean body mass and decreased fat mass in treated animals over study periods of several weeks
- In porcine models, CJC-1295 stimulated pulsatile GH release with peak levels occurring at predictable intervals
Selectivity:
- CJC-1295 is highly selective for the GHRH receptor
- It does not significantly stimulate release of cortisol, prolactin, or other pituitary hormones at doses that produce robust GH release
- This selectivity is a key distinction from less selective GHSs
Ipamorelin
Overview
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a). It was developed by Novo Nordisk in the late 1990s and is distinguished from other GHS-R agonists by its high selectivity for GH release.
Molecular weight: 711.85 Da
Mechanism of Action
Ipamorelin binds to GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, stimulating GH release through a signaling pathway distinct from the GHRH pathway. The ghrelin pathway amplifies the effect of endogenous GHRH, making the two pathways synergistic rather than redundant.
What distinguishes Ipamorelin from other GHS-R agonists is its remarkable selectivity. In animal studies, Ipamorelin released GH with an efficacy and potency comparable to GHRP-6, but without significant stimulation of ACTH, cortisol, prolactin, or aldosterone at GH-releasing doses.
Key Research Findings
Animal studies:
- In rats, Ipamorelin stimulated dose-dependent GH release with an ED50 of approximately 80 nmol/kg (IV)
- In swine models, Ipamorelin produced robust GH peaks without elevating cortisol or prolactin
- Repeated administration in animal models did not produce tachyphylaxis (loss of response) over study periods of up to 15 days
- In aged rat models, Ipamorelin restored GH secretion toward levels observed in younger animals
Selectivity data (from animal studies):
- At doses producing maximal GH release, cortisol levels remained at baseline
- ACTH levels were not significantly affected
- Prolactin was not stimulated
- FSH and LH were unaffected
- TSH was not altered
This selectivity profile is considered the cleanest among commercially available GHS-R agonists.
GHRP-6
Overview
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that was one of the first synthetic GHSs developed. It is a potent activator of GHS-R1a and produces robust GH release, but with a less selective pharmacological profile than Ipamorelin.
Molecular weight: 873.01 Da
Mechanism of Action
Like Ipamorelin, GHRP-6 binds to GHS-R1a on pituitary somatotrophs. However, GHRP-6 also activates additional signaling pathways and affects the release of multiple hormones beyond GH.
Key Research Findings
Animal studies:
- In rodent models, GHRP-6 produced robust, dose-dependent GH release
- In addition to GH, GHRP-6 stimulated release of ACTH and cortisol in a dose-dependent manner
- GHRP-6 increased prolactin levels in animal models at GH-releasing doses
- In dog models, GHRP-6 administration was associated with a significant increase in appetite and food intake (consistent with its activity at the ghrelin receptor, which also controls appetite)
- In cardiac ischemia-reperfusion models in rats, GHRP-6 demonstrated cardioprotective effects independent of GH release
Non-GH effects:
- Appetite stimulation: GHRP-6 is a potent appetite stimulant in animal models, consistent with its ghrelin-mimetic activity
- Cortisol release: GHRP-6 stimulates the HPA axis, resulting in cortisol elevation
- Prolactin release: Moderate prolactin elevation has been observed in animal studies
- Gastric motility: GHRP-6 increases gastric motility and acid secretion in animal models
Comparative Analysis
GH Release Potency
All three peptides are effective GH secretagogues, but they differ in mechanism and kinetics:
| Parameter | CJC-1295 (no DAC) | Ipamorelin | GHRP-6 |
|---|---|---|---|
| Receptor target | GHRH-R | GHS-R1a | GHS-R1a |
| GH release onset | 15-30 min | 5-15 min | 5-15 min |
| GH peak duration | 2-3 hours | 1-2 hours | 1-2 hours |
| Half-life | ~30 min | ~2 hours | ~20 min |
| Relative GH potency | Moderate | High | High |
Selectivity Profile
This is where the three peptides differ most significantly:
| Hormone | CJC-1295 | Ipamorelin | GHRP-6 |
|---|---|---|---|
| Growth Hormone | Increased | Increased | Increased |
| Cortisol | No change | No change | Increased |
| Prolactin | No change | No change | Increased |
| ACTH | No change | No change | Increased |
| Appetite | No change | Minimal | Significantly increased |
Ipamorelin offers the cleanest selectivity profile among the GHS-R agonists, making it preferred for research where confounding hormonal changes could complicate data interpretation.
GHRP-6 produces the broadest hormonal response, which may be advantageous for research specifically investigating multi-hormone interactions or appetite regulation, but disadvantageous when isolated GH effects are the research goal.
CJC-1295 is highly selective through the GHRH pathway and is often studied in combination with GHS-R agonists (particularly Ipamorelin) due to the synergistic nature of the GHRH and ghrelin pathways on GH release.
Synergistic Combinations
The combination of a GHRH analog (CJC-1295) with a GHS-R agonist (Ipamorelin) has been studied in animal models and represents a research approach that leverages the synergy between the two GH-releasing pathways:
- In rodent models, the combination of CJC-1295 + Ipamorelin produced greater GH release than either peptide alone
- The amplitude of GH pulses was increased while maintaining physiological pulsatile patterns
- The combination did not produce synergistic effects on cortisol or prolactin (maintaining the clean selectivity profile)
This combination approach is one of the most commonly studied GHS protocols in current peptide research.
Research Considerations
Assay Interference
Researchers studying these peptides should be aware of potential interference with downstream assays:
- GHRP-6's cortisol-elevating effects may confound stress response research
- Appetite stimulation from GHRP-6 may alter feeding patterns and metabolic endpoints in long-term animal studies
- CJC-1295 with DAC's extended half-life may complicate pharmacokinetic analyses
Peptide Quality
For reliable research results with growth hormone secretagogues:
- Purity: >98% by HPLC is recommended for quantitative GH release studies
- Identity: Mass spectrometry confirmation is essential, particularly for distinguishing CJC-1295 with and without DAC
- Storage: All three peptides should be stored lyophilized at -20C and reconstituted solutions at 2-8C
- Source consistency: Batch-to-batch variability can introduce noise into longitudinal studies. Use the same vendor and request same-batch material for multi-part studies when possible.
Current Research Directions
Active areas of investigation include:
- Aging research: The effect of GHS administration on age-related decline in GH secretion in animal models
- Body composition: Longitudinal studies of lean mass and fat mass changes in treated versus control animals
- Cardioprotection: GHRP-6 and related peptides in cardiac ischemia-reperfusion models
- Bone density: Effects of sustained GH elevation on bone mineral density in aged animal models
- Combination protocols: Optimization of CJC-1295 + Ipamorelin dosing for maximal GH response with minimal side effects
Conclusion
CJC-1295, Ipamorelin, and GHRP-6 represent three distinct approaches to stimulating growth hormone release in research settings. Ipamorelin stands out for its selectivity, GHRP-6 for its potency and multi-hormone effects, and CJC-1295 for its sustained action through the GHRH pathway. The choice between them — or the decision to combine them — should be guided by the specific research question being addressed, with careful consideration of their differing selectivity profiles and potential confounding effects on non-GH endpoints.
This article is a comparative review of published research literature for educational purposes only. All peptides discussed are for laboratory research use only and are not intended for human consumption. No therapeutic claims are made or implied.